small-molecule NLRP3 inhibitor

Small-molecule NLRP3 inhibitors are a class of therapeutic agents designed to target and inhibit the NOD-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome, a key mediator of inflammatory responses and pyroptosis. In the context of neurodegenerative diseases like Alzheimer's disease, these brain-penetrant small molecules aim to suppress microglial activation and neuroinflammation. A specific preclinical asset in this class, developed by Sanofi and referred to as sNLRP3i (or sLRPi), has demonstrated potent inhibition of IL-1β release and pyroptosis in microglia, showing neuroprotective effects in Alzheimer's disease models and metabolic benefits in obesity models.

Other names

sLRPi